Ram Waisbourd - 17 Feb 2022 Form 4 Insider Report for 89bio, Inc. (ETNB)

Role
Chief Operating Officer and Chief Business Officer
Signature
/s/ Ryan A. Murr, as attorney-in-fact for Ram Waisbourd
Issuer symbol
ETNB
Transactions as of
17 Feb 2022
Net transactions value
$0
Form type
4
Filing time
22 Feb 2022, 16:13:20 UTC
Previous filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETNB Common Stock Award $0 +6,250 $0.000000 6,250 17 Feb 2022 Direct F1
transaction ETNB Common Stock Award $0 +2,500 +40% $0.000000 8,750 17 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETNB Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 17 Feb 2022 Common Stock 25,000 $4.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") that vest with respect to one-third of the underlying shares on February 17, 2023, with the remaining two-thirds vesting in equal semi-annual installments over the following two years, subject to the Reporting Person's continued service to the Issuer.
F2 Represents RSUs that vest in equal installments on each of August 1, 2022, February 1, 2023 and August 1, 2023.
F3 This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, one quarter of which will vest on February 17, 2023, with the remaining three quarters vesting in equal quarterly installments over the following three years, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Chief Operating Officer and Chief Business Officer